Giant pituitary adenoma: histological types, clinical features and therapeutic approaches
- PMID: 29909598
- DOI: 10.1007/s12020-018-1645-x
Giant pituitary adenoma: histological types, clinical features and therapeutic approaches
Abstract
Giant pituitary adenomas comprise about 6-10% of all pituitary tumors. They are mostly clinically non-functioning adenomas and occur predominantly in males. The presenting symptoms are usually secondary to compression of neighboring structures, but also due to partial or total hypopituitarism. Functioning adenomas give rise to specific symptoms of hormonal hypersecretion. The use of dopamine agonists is considered a first-line treatment in patients with giant macroprolactinomas. Somatostatin analogs can also be used as primary treatment in cases of growth hormone and thyrotropin producing giant adenomas, although remission of the disease is not achieved in the vast majority of these patients. Neurosurgical treatment, either through transsphenoidal or transcranial surgery, continues to be the treatment of choice in the majority of patients with giant pituitary adenomas. The intrinsic complexity of these tumors requires the use of different therapies in a combined or sequential way. A multimodal approach and a therapeutic strategy involving a multidisciplinary team of expert professionals form the basis of the therapeutic success in these patients.
Keywords: Acromegaly; Clinically non-functioning pituitary adenoma; Giant pituitary adenoma; Medical therapy; Neurosurgery; Prolactinoma; Radiotherapy.
Similar articles
-
[Treatment of pituitary adenomas].Orv Hetil. 2009 Sep 27;150(39):1803-10. doi: 10.1556/OH.2009.28584. Orv Hetil. 2009. PMID: 19758960 Review. Hungarian.
-
Diagnosis and treatment of pituitary adenomas.Minerva Endocrinol. 2004 Dec;29(4):241-75. Minerva Endocrinol. 2004. PMID: 15765032 Review.
-
Pituitary Adenomas: What Are the Key Features? What Are the Current Treatments? Where Is the Future Taking Us?World Neurosurg. 2019 Jul;127:695-709. doi: 10.1016/j.wneu.2019.03.049. World Neurosurg. 2019. PMID: 31266132
-
Non-functioning pituitary adenomas.J Endocrinol Invest. 2005;28(11 Suppl International):93-9. J Endocrinol Invest. 2005. PMID: 16625856 Review.
-
Clinically non-functioning pituitary adenomas: Pathogenic, diagnostic and therapeutic aspects.Endocrinol Diabetes Nutr. 2017 Aug-Sep;64(7):384-395. doi: 10.1016/j.endinu.2017.05.009. Epub 2017 Jul 4. Endocrinol Diabetes Nutr. 2017. PMID: 28745610 Review. English, Spanish.
Cited by
-
The expression of VDACs and Bcl2 family genes in pituitary adenomas: clinical correlations and postsurgical outcomes.Front Endocrinol (Lausanne). 2024 Oct 10;15:1481050. doi: 10.3389/fendo.2024.1481050. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39449743 Free PMC article.
-
Giant growth hormone-secreting pituitary adenomas from the endocrinologist's perspective.Endocrine. 2023 Mar;79(3):545-553. doi: 10.1007/s12020-022-03241-2. Epub 2022 Nov 1. Endocrine. 2023. PMID: 36318446
-
Comparative Proteomic Study Shows the Expression of Hint-1 in Pituitary Adenomas.Diagnostics (Basel). 2021 Feb 17;11(2):330. doi: 10.3390/diagnostics11020330. Diagnostics (Basel). 2021. PMID: 33671384 Free PMC article.
-
Acromegaly complicated with fulminant pituitary apoplexy: clinical characteristic analysis and review of literature.Endocrine. 2023 Jul;81(1):160-167. doi: 10.1007/s12020-023-03379-7. Epub 2023 May 17. Endocrine. 2023. PMID: 37195580 Free PMC article. Review.
-
Giant and irregular pituitary neuroendocrine tumors surgery: comparison of simultaneous combined endoscopic endonasal and transcranial and purely endoscopic endonasal surgery at a single center.Chin Neurosurg J. 2025 Feb 3;11(1):3. doi: 10.1186/s41016-025-00389-4. Chin Neurosurg J. 2025. PMID: 39894800 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical